Education
About Us
Working with TipRanks
Follow Us
Editas Medicine Inc. (GB:0IFK)
:0IFK
0IFK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.92 - $6.20
Previous CloseN/A
Volume18.42K
Average Volume (3M)35.78K
Market Cap
$137.29M
Enterprise ValueN/A
Total Cash (Recent Filing)$269.91M
Total Debt (Recent Filing)$35.03M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Jul 30, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding83,712,860
10 Day Avg. Volume51,860
30 Day Avg. Volume35,781
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-0.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.11Price Target Upside86.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Editas Medicine News
Bulls Say, Bears Say
Bulls Say
Analyst RatingsAnalyst recommends a buy rating, indicating confidence in the company's future prospects and technology.
Financial StabilityEditas ended 1Q25 with $221M in cash and cash equivalents, which Editas expects should provide an operational runway into 2Q27.
Gene Editing TechnologyEditas announced achieving preclinical proof of concept for its in vivo gene editing approach, which supports the potential of its technology.
Bears Say
Financial PerformanceEditas reported a net loss of $0.92 per share in 1Q25 vs. prior estimate of a net loss of $0.55 per share.
Market ExpectationsEditas reported a net loss per share that was larger than the consensus expectations.
Patent UncertaintyThere is increasing uncertainty surrounding the Cas9 patent interference case as it has been remanded back to the PTAB for reconsideration.
Options Prices
Currently, No data available
---
Ownership Overview
0.81% Insiders
14.32%
Mutual Funds
0.74% Other Institutional Investors
71.75% Public Companies and Individual Investors
0IFK FAQ
What was Editas Medicine Inc.’s price range in the past 12 months?
Editas Medicine Inc. lowest share price was $0.92 and its highest was $6.20 in the past 12 months.
What is Editas Medicine Inc.’s market cap?
Editas Medicine Inc.’s market cap is $137.29M.
When is Editas Medicine Inc.’s upcoming earnings report date?
Editas Medicine Inc.’s upcoming earnings report date is Jul 30, 2025 which is in 68 days.
How were Editas Medicine Inc.’s earnings last quarter?
Editas Medicine Inc. released its earnings results on May 12, 2025. The company reported -$0.92 earnings per share for the quarter, missing the consensus estimate of -$0.564 by -$0.356.
Is Editas Medicine Inc. overvalued?
According to Wall Street analysts Editas Medicine Inc.’s price is currently Undervalued.
Does Editas Medicine Inc. pay dividends?
Editas Medicine Inc. does not currently pay dividends.
What is Editas Medicine Inc.’s EPS estimate?
Editas Medicine Inc.’s EPS estimate is -0.4.
How many shares outstanding does Editas Medicine Inc. have?
Editas Medicine Inc. has 83,712,860 shares outstanding.
What happened to Editas Medicine Inc.’s price movement after its last earnings report?
Editas Medicine Inc. reported an EPS of -$0.92 in its last earnings report, missing expectations of -$0.564. Following the earnings report the stock price went down -1.661%.
Which hedge fund is a major shareholder of Editas Medicine Inc.?
Currently, no hedge funds are holding shares in GB:0IFK
Editas Medicine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.11 (86.23% Upside)
$3.11 (86.23% Upside)
Blogger Sentiment
Bullish
GB:0IFK Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.77%
12-Months-Change
Fundamentals
Return on Equity
-140.82%
Trailing 12-Months
Asset Growth
-40.13%
Trailing 12-Months
Company Description
Editas Medicine Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
0IFK Stock 12 Month Forecast
Average Price Target
$3.11
▲( 86.23% Upside)
Technical Analysis
Cellectis SA
―
RAPT Therapeutics
―
Nkarta
―
Neumora Therapeutics, Inc.
―
Contineum Therapeutics, Inc. Class A
―